Browse our 1,000+ Publications​

Latest Publications

Dasatinib-based induction and blinatumomab + TKI consolidation/maintenance forBCR::ABL1+ ALL: BLISSPhALL Study Results

Geyer M, et al.
Blood Neoplasia
September 2026
Authors and Affiliates
Mark Geyer(Medicine,Memorial Sloan Kettering Cancer Center,United States) John Mascarenhas(Hematology Oncology,Icahn School of Medicine at Mount Sinai,United States) Michal Bar- Natan(,Weill Cornell Medical College and New York-Presbyterian Hospital,United States) Marissa Smith(,Memorial Sloan Kettering Cancer Center,United States) Shakira Pascual(,Memorial Sloan Kettering Cancer Center,United States) Anmol Shah(,Memorial Sloan Kettering Cancer Center,United States) Michael Silvestrone(Clinical Research Administration,Memorial Sloan Kettering Cancer Center,United States) Kenton Wu(,Memorial Sloan Kettering Cancer Center,United States) Hannah Levavi(,Icahn School of Medicine at Mount Sinai,United States) Tina Czaplinska(,Icahn School of Medicine at Mount Sinai,United States) Kathryn Johnson(,Ichan School of Medicine at Mount Sinai,United States) Meghan Thompson(,Memorial Sloan Kettering Cancer Center,United States) Eytan Stein(Leukemia Service, Department of Medicine,Memorial Sloan Kettering Cancer Center,United States) Yanming Zhang(Pathology,Memorial Sloan Kettering Cancer Center,United States) Andriy Derkach(,Memorial Sloan-Kettering Cancer Center,United States) Jae Park(Leukemia Service,Memorial Sloan-Kettering Cancer Center,United States)

Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory AcuteLymphoblastic Leukemia

Luskin M, et al.
Blood
September 2026
Authors and Affiliates
Marlise Luskin (Dana-Farber Cancer Institute, United States) Julia Keating (Dana-Farber Cancer Institute, United States) Benjamin Frost (Brigham and Women's Hospital, United States) Stella Jaeckle (Dana-Farber Cancer Institute, United States) Shai Shimony (Dana-Farber Cancer Institute, United States) Yael Flamand (Dana-Farber Cancer Institute, United States) Jacqueline Garcia (Dana Farber Cancer Institute, United States) Richard Stone (Dana-Farber Cancer Institute, United States) Matthew Booker (Dana-Farber Cancer Institute, United States) Chase Weizer (Dana-Farber Cancer Institute, United States) Jeremy Ryan (Dana-Farber Cancer Institute, United States) Jessica Lee (Dana-Farber Cancer Institute, United States) Ilene Galinsky (Dana Farber Cancer Institute, Harvard, United States) Sujal Shah (Brigham & Women's Hospital, United States) Emma Smith (Dana Farber Cancer Institute, United States) Arpita Kulkarni (Harvard Medical School, United States) Michael Tolstorukov (Dana-Farber Cancer Institute, United States) Evan Chen (Dana-Farber Cancer Institute, United States) Eric Winer (Dana-Farber Cancer Institute, United States) Anthony Letai (Dana-Farber Cancer Institute, United States) Mark Murakami (Dana-Farber Cancer Institute, United States) Daniel DeAngelo (Dana-Farber Cancer Institute, United States)

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

Dekhtiarenko I, et al.
Blood Advances
September 2026
Authors and Affiliates
Iryna Dekhtiarenko (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Jan Attig (Roche Innovation Center Basel, pRED, Switzerland) Iva Lelios (Roche Innovation Center Basel, pRED, Switzerland) Stephan Schmeing (Roche Innovation Center Basel, pRED, Switzerland) Carmen Yong (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Wolfgang Jacob (Roche Innovation Center Munich, pRED, Germany) Emilio Yángüez (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Tamara Hüsser (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Llucia Albertí Servera (Roche Innovation Center Basel, pRED, Switzerland) Inga Clausen (Roche Innovation Center Basel, pRED, Switzerland) Hans Grote (Roche Innovation Center Munich, pRED, Germany) Cláudia Ferreira (Roche Innovation Center Munich, pRED, Switzerland) Hans-Joachim Helms (Roche Innovation Center Basel, pRED, Switzerland) Cristina Santini (Roche Innovation Center Basel, pRED, Switzerland) Emilie Schindler (Roche Innovation Center Basel, pRED, Switzerland) Sylvia Herter (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Marina Bacac (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Carmelo Carlo-Stella (Humanitas University and IRCCS Humanitas Research Hospital, Italy) Anna Caroline Hasselbalch (Rigshospitalet, Denmark) Salomon Manier (CHU de Lille, France) Antonio Pinto (Istituto Nazionale dei Tumori "Fondazione G Pascale", IRCCS, Italy) Paolo Corradini (IRCCS Istituto Nazionale dei Tumori, University of Milano, Italy) Cyrille Hulin (CHU de Bordeaux, France) Sung-Soo Yoon (Seoul National University College of Medicine, Korea, Republic of) Rakesh Popat (NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, United Kingdom) Simon Harrison (Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Australia) Martin Weisser (Roche Innovation Center Munich, pRED, Germany) Ann- Marie Bröske (Roche Innovation Center Munich, pRED, Germany)

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractoryB-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 resultsfrom a single-arm, multicentre, phase 1/2 study

Kersten M, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Marie José Kersten 1, Maria T Kuipers 2, Pim G N J Mutsaers 3, Evelyne Willems 4, Kirsten Saevels 5, Martin Dreyling 6, Caron Jacobson 7, Michael R Bishop 8, Maarten Zandvliet 9, Stavros Milatos 10, Chiara Lobetti-Bodoni 10, Sandra Blum 10, Kirsten Van Hoorde 11, Jigar Desai 12, Lorenzo Acciarri 13, Margot J Pont 9, Anna van Muyden 9, Omotayo Fasan 12, Joost S P Vermaat 14, Sébastien Anguille 5 1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: m.j.kersten@amsterdamumc.nl. 2Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. 3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4Department of Hematology, Centre Hospitalier Universitaire de Liège, Liège, Belgium. 5Division of Hematology and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium. 6Department of Medicine III, LMU Hospital Munich, Munich, Germany. 7Division of Lymphoma, Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. 8The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA. 9Galapagos, Leiden, Netherlands; CellPoint, Leiden, Netherlands. 10Galapagos, Basel, Switzerland. 11Open Analytics, Antwerp, Belgium. 12Galapagos, Princeton, NJ, USA. 13Valos, Genoa, Italy. 14Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Falchi L, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Lorenzo Falchi 1, Joost S P Vermaat 2, Joshua D Brody 3, Lori Leslie 4, Fritz Offner 5, Jacob Haaber Christensen 6, Marcel Nijland 7, David Belada 8, Björn Engelbrekt Wahlin 9, Kristina Drott 10, Pilar Gomez Prieto 11, Kateřina Kopečkova 12, Alejandro Martín García-Sancho 13, Jian P Mei 14, Işıl Altıntaş 15, Malene Risum 16, Aidan Reilly 17, Jun Zou 17, Pau Abrisqueta 18 1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: falchil@mskcc.org. 2Leiden University Medical Center, Leiden, Netherlands. 3Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA. 5Universitair Ziekenhuis Gent, Ghent, Belgium. 6Odense University Hospital, Odense, Denmark. 7University Medical Center Groningen and University of Groningen, Groningen, Netherlands. 8Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic. 9Karolinska Institutet, Stockholm, Sweden. 10Skåne University Hospital, Lund, Sweden. 11Hospital Universitario La Paz, Madrid, Spain. 12Motol University Hospital, Charles University, Prague, Czech Republic. 13Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain. 14AbbVie, North Chicago, IL, USA. 15Genmab, Utrecht, Netherlands. 16Genmab, Copenhagen, Denmark. 17Genmab, Plainsboro, NJ, USA. 18Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Gould P, et al.
Haematologica
August 2026
Authors and Affiliates
*Patrick Gould,1,2 *Devyn Coskey,1 Xin Ma,1 Shikun Wang,1 Sonia Godbole,3 David Bond,3 Andrew Ip,4 Snegha Ananth,5 Shaunak Varma,6 Emily Ayers,6 Rachel Faden,7 Cassandra Gillespie,7 Basem William,7 Ryan Jacobs,8 Bei Hu,8 Jake Lattin,9 David Russler-Germain,9 Michele Stanchina,10 Ashley Rose,10 Michael Randall,11 Michael Spinner,11 Vidiya Srikakulapu,12 Praveen Ramakrishnan Geethakumari,12 Alan Skarbnik,13 David W. Chitty,14 Mazie Tsang,15 Cassandra Duarte,16 Ajay Major,16 Allison M. Bock,17 Kelsey Baron,17 Brian Hess,18 Seda Tolu,1 Barbara Pro,1 Supriya Vaidya,1 Jennifer E. Amengual,1 Ran Reshef,1 Hua-Jay J. Cherng1# 1Columbia University Irving Medical Center, New York, NY; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Ohio State University, Columbus, OH; 4Hackensack University Medical Center, Hackensack, NJ; 5University of Nebraska, Omaha, NE; 6University of Virginia, Charlottesville, VA; 7OhioHealth, Columbus, OH; 8Levine Cancer Institute, Atrium Health Wake Forest, Charlotte, NC; 9Washington University in St. Louis, St. Louis, MO; 10University of Miami, Miami, FL; 11University of California San Francisco, San Francisco, CA; 12University of Texas, Southwestern, Dallas, TX; 13Novant Health Cancer Institute, Charlotte, NC; 14Northwell Health, Lake Success, NY; 15Mayo Clinic Arizona, Phoenix, AZ; 16University of Colorado, Aurora, CO; 17University of Utah, Salt Lake City, UT; 18Medical University of South Carolina, Charleston, SC *P. G. and D. C contributed equally to this study

Tracking B-cell Depletion and Reconstitution using Next-Generation Immunosequencing

Lee L, et al.
Blood Immunology & Cellular Therapy
August 2026
Authors and Affiliates
Lik Wee Lee (Adaptive Biotechnologies Corp., United States) Rohaum Hamidi (Stanford University School of Medicine, United States) Christina Baggott (Stanford University, United States) Liora Schultz (Columbia University Medical Center, United States) Ilan Kirsch (Adaptive Biotechnologies, United States)

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Wierda W, et al.
Blood
July 2026
Authors and Affiliates
William Wierda (The University of Texas MD Anderson Cancer Center, United States) Kathleen Dorritie (UPMC, United States) Jordan Gauthier (Fred Hutchinson Cancer Research Center, United States) Rajneesh Nath (Banner MD Anderson Cancer Center, United States) Thomas Kipps (University of California, San Diego School of Medicine, United States) Peter Riedell (The David and Etta Jonas Center for Cellular Therapy, University of Chicago, United States) Herbert Eradat (UCLA, United States) Saad Kenderian (Mayo Clinic, United States) Mohamed Kharfan-Dabaja (Mayo Clinic, United States) Nirav Shah (Medical College of Wisconsin, United States) Scott Solomon (Northside Hospital Cancer Institute, United States) Deborah Stephens (Lineberger Cancer Center, University of North Carolina, United States) Daniel Ermann (Huntsman Cancer Institute, University of Utah, United States) Jon Arnason (Beth Israel Deaconess Medical Center, United States) Abhinav Deol (Wayne State University, United States) Tatyana Feldman (Hackensack University Medical Center, United States) Charalambos Andreadis (University of California San Francisco, United States) Monalisa Ghosh (University of Michigan, United States) Shuo Ma (Northwestern University, United States) Stephen Schuster (Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, United States) Usama Gergis (Thomas Jefferson University, United States) Julie Vose (University of Nebraska Medical Center, United States) Jacob Soumerai (Mass General Brigham Cancer Institute, United States) Koen van Besien (Seidman Cancer Center, United States) Sherilyn Tuazon (Bristol Myers Squibb, United States) Serena Perna (Bristol Myers Squibb, United States) San-San Ou (Bristol Myers Squibb, United States) Revathi Ananthakrishnan (Bristol Myers Squibb, United States) Neha Rane (Bristol Myers Squibb, United States) Eniko Papp (Bristol Myers Squibb, United States) Sahar Ansari (Bristol Myers Squibb, United States) Ethan Thompson (Bristol Myers Squibb, United States) Abood Okal (Bristol Myers Squibb, United States) Leanne Peiser (Bristol Myers Squibb, United States) Yizhe Chen (Bristol Myers Squibb, United States) Sanhita Sengupta (Bristol Myers Squibb, United States) Pradipta Ray (Bristol Myers Squibb, United States) Jixian Wang (Bristol Myers Squibb, Switzerland) Tanya Siddiqi (City of Hope Orange County, United States)

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage

Azavedo R, et al.
Leukemia
July 2026
Authors and Affiliates
Roberta S. Azevedo 1,3, Elias Jabbour 1,3, Nitin Jain1, Fadi G. Haddad 1, Partow Kebriaei 2, Issa Khouri 2, Elizabeth J. Shpall2, Richard Champlin 2, Omer Karrar 1, Manuel Maroun 1, Jayastu Senapati 1, Eitan Kugler1, Rebecca S. Garris1, Farhad Ravandi 1, Hagop Kantarjian 1 and Nicholas J. Short 1 1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, USA. 2The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, USA. 3These authors contributed equally: Roberta S. Azevedo, Elias Jabbour.

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

Altintas I, et al.
Blood Advances
July 2026
Authors and Affiliates
Isil Altintas (Genmab, Netherlands) Christopher Morehouse (Genmab, United States) Elena Favaro (Genmab A/S, Denmark) Ali Rana (Genmab, United States) John Karavitis (Genmab, United States) Edith Szafer Glusman (AbbVie, United States) Kevin Zhao (AbbVie, United States) Kim Linton (The University of Manchester, United Kingdom) Alexey Danilov (City of Hope, United States) Ann LaCasce (Dana-Farber Cancer Institute, United States) Lorenzo Falchi (Memorial Sloan Kettering Cancer Center, United States) Jessica Okosun (Barts Cancer Institute, Queen Mary University of London, United Kingdom) Tahamtan Ahmadi (Genmab, United States) Mark Fereshteh (Genmab, United States) Maria Jure-Kunkel (Genmab, United States) David Soong (Genmab, United States) Andrew Steele (Genmab, United States)
Previous Next